AKYA Insider Trading

Insider Ownership Percentage: 7.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $30,675.00

Akoya Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Akoya Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Akoya Biosciences Share Price & Price History

Current Price: $1.43
Price Change: Price Decrease of -0.06 (-4.03%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for AKYA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$1.43Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for Akoya Biosciences (NASDAQ:AKYA)

79.42% of Akoya Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AKYA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$992kbought$240ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal InflowsTotal Outflows
Akoya Biosciences logo
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Read More on Akoya Biosciences

Today's Range

Now: $1.43
Low: $1.39
High: $1.49

50 Day Range

MA: $2.11
Low: $1.43
High: $3.23

52 Week Range

Now: $1.43
Low: $1.39
High: $4.69

Volume

76,983 shs

Average Volume

349,572 shs

Market Capitalization

$71.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Who are the company insiders with the largest holdings of Akoya Biosciences?

Akoya Biosciences' top insider investors include:
  1. Matthew Winkler (Director)
  2. Brian Mckelligon (CEO)
  3. Frederic Pla (COO)
  4. John Frederick Ek (CFO)
Learn More about top insider investors at Akoya Biosciences.

Who are the major institutional investors of Akoya Biosciences?

Akoya Biosciences' top institutional investors include:
  1. Paragon Associates & Paragon Associates II Joint Venture — 1.62%
  2. SVB Wealth LLC — 1.04%
  3. Northern Trust Corp — 0.51%
  4. Schonfeld Strategic Advisors LLC — 0.25%
  5. Deutsche Bank AG — 0.11%
  6. Bank of New York Mellon Corp — 0.10%
Learn More about top institutional investors of Akoya Biosciences stock.

Which major investors are selling Akoya Biosciences stock?

Within the last quarter, AKYA stock was sold by these institutional investors:
  1. Schonfeld Strategic Advisors LLC
  2. Jane Street Group LLC
  3. Bank of New York Mellon Corp

Which major investors are buying Akoya Biosciences stock?

In the last quarter, AKYA stock was bought by institutional investors including:
  1. SVB Wealth LLC
  2. Deutsche Bank AG
  3. Northern Trust Corp
  4. JPMorgan Chase & Co.
  5. Price T Rowe Associates Inc. MD
  6. SG Americas Securities LLC
  7. Intech Investment Management LLC
  8. Paragon Associates & Paragon Associates II Joint Venture
During the last year, these company insiders have bought Akoya Biosciences stock:
  1. Matthew Winkler (Director)
  2. Brian Mckelligon (CEO)
  3. Frederic Pla (COO)
Learn More investors buying Akoya Biosciences stock.